Healthcare reform regulations, increasing costs, and more competition are driving employers and their health plans to focus more than ever on opportunities to reduce cost trends. For example, the country experienced a 3.0% growth in per capita gross (allowed) medical and pharmacy costs from 2012 to 2013. Truven Health Analytics anticipates those costs in 2014 and 2015 will increase by 4% to 5% or more. By taking a data-driven approach, payers can manage costs and, ultimately, make their benefit programs sustainable in the context of healthcare reform. They can also maximize opportunities to improve population health and productivity and optimize the delivery of care.
Spending on supplies and pharmaceutical services varies among U.S. hospitals. It is not uncommon for hospitals with similar types of patients, including case mix and severity, to have significant differences in purchasing intensity for certain clinical services. Even small changes in efficiency can make a difference for hospitals and health systems, because supply-chain spending typically accounts for hospitals’ biggest spend after labor costs. Costs totaled about $74 billion in 2012, according to the Healthcare Supply Chain Association.
Business Spend Management Improves Visibility and Control Over Spend for Financial Leaders
Closing the books can be a tedious, manual process when accrual balances don’t match AP balances and a backlog of invoices cause an increase in resource hours.
Get insight on how Salesforce and Ionis Pharmaceuticals leverage business spend management to streamline the financial close.
Read this eBook to learn how to:
• Automate spend processes to cut heavy manual workloads
• Gain full visibility and control over spend
• Move from transactional “spreadsheet jockey” to strategic management
• Minimize risk associated with missed accruals
Healthcare and Life Sciences organizations are using data to generate knowledge that helps them provide better patient care, enhances biopharma research and development, and streamlines operations across the product innovation and care delivery continuum. Next-Gen business intelligence (BI) solutions can help organizations reduce time-to-insight by aggregating and analyzing structured and unstructured data sets in real or near-real time.
AWS and AWS Partner Network (APN) Partners offer technology solutions to help you gain data-driven insights to improve care, fuel innovation, and enhance business performance.
In this webinar, you’ll hear from APN Partners Deloitte and hc1.com about their solutions, built on AWS, that enable Next-Gen BI in Healthcare and Life Sciences.
Join this webinar to learn:
How Healthcare and Life Sciences organizations are using cloud-based analytics to fuel innovation in patient care and biopharmaceutical product development.
How AWS supports BI solutions f
Patients are going digital — and taking the healthcare system with them. Learn how in the 2017 Digital Trends in Healthcare and Pharma report.
Download it now to learn:
Why two-thirds of healthcare companies are investing in data analysis.
How they’re building content marketing programs to boost patient knowledge.
What they plan to do with virtual and augmented reality this year and beyond.
When a pharmaceutical company discovered its risks under the new Patient Protection and Affordable Care Act, it turned to Collaborative to comb and consolidate its data. The result: compliance and insight into new business opportunities, too, through a company-wide business data warehouse and enhanced business intelligence.
In a panel discussion at the 12th annual SAS Health Analytics
Executive Forum in May 2015, leaders from Dignity Health,
Horizon Blue Cross Blue Shield of New Jersey, Janssen
Pharmaceuticals and SAS shared what they have done to prove
the value of analytics to their business leaders – and what has
worked for them as they developed an analytic culture in their
organizations and put analytic insights to work.
To the casual observer, aircraft manufacturer Airbus UK and pharmaceutical giant GlaxoSmithKline (GSK) wouldn't appear to share a lot of common ground. Some would say that the worlds of building airplanes and producing the next blockbuster wonder-drug are light years apart. A closer look shows that these two organizations are more similar than one might initially think.
Cost reduction is a key criteria that executives often use when choosing initiatives to focus on. They are the ones that have the greatest potential to impact an organization's bottom line. Across life science organizations, a critical area for cost containment is training management.
This paper summarizes the results of a quantitative benchmarking survey to over 200 Life Science organizations. The study identifies the key compliance and performance improvement training topics they had addressed in 2011 along with key issues for 2012.
SOPs are critical to efficient manufacturing operations, quality control, and regulatory compliance. This paper reviews best practices for the Life Science industry for training on SOPs, and how learning management technology has the potential to improve learner retention through automated assessments.
Third party intermediaries have played starring roles in some of the most highly publicized global corruption trials. By any measure, third party intermediaries routinely rank high on the list of compliance worries for brand companies.
Good Manufacturing Practices (GMP) violations have become the new healthcare fraud as the Department of Justice (DOJ) tests out new legal theories under the False Claims Act (FCA). The Food and Drug Administration (FDA) has dusted off its regulatory authority to prosecute GMP violations.
Published By: Intermec
Published Date: Jun 20, 2013
This research, commissioned by Intermec and carried out by research company Vanson Bourne, surveyed 250 senior supply chain and distribution center managers at organizations with over 500 employees in the UK, France, Germany and North America. The interviews were conducted by telephone with respondents spanning industries including retail, manufacturing, distribution, transport, chemicals, logistics, pharmaceuticals, wholesale and FMCG. 50 interviews were conducted in each European country with 100 interviews taking place in North America during October 2012.
For life sciences businesses, the supply chain used to mean one thing: getting products from factory or warehouse to distributors or ultimate customers as quickly and economically as possible. Now, with today’s evolving regulatory environment, an increasingly globalized market, more complex health products, and an increased focus on the patient, pharmaceutical companies and medical device manufacturers are looking at their supply chain and logistics needs in a whole new way.
One-fourth of all healthcare products today are temperature-sensitive and that number is growing. For many pharmaceutical or biologic shipments, 2 degrees Celsius is all that separates medicine from becoming spoiled inventory and a costly write-off. Here are four risk mitigation strategies for temperature-sensitive shipments.
Managing pain is vital to how hospitals are measured on patient satisfaction. Learn how a hospital uses an interactive patient care solution to streamline pain feedback, integrating with an EMR, nursing notification and pharmacy dispensing systems.
Top 5 Factors Every Bio-Tech and Pharmaceutical Company Must Keep in Mind.
Successfully launching a product in the U.S. requires a balance across commercial strategy, government programs, and contracting operations. While the market holds significant opportunity, there are also complexities that need to be considered prior to launch.
To prepare for the launch of your drug in the U.S. market, download a copy of Navigating the U.S. Government Market to help your organization remain compliant with government operational and pricing requirements.
Download this white paper for a deeper look into the growing question surrounding the pharmaceutical industry--If customer centricity is so widely accepted as a way to unlock significant financial gains, why are companies so slow to adopt it?